Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study

被引:12
作者
Koh, KK
Son, JW
Ahn, JY
Jin, DK
Kim, HS
Kim, DS
Han, SH
Chung, WJ
Park, GS
Shin, EK
机构
[1] Gachon Med Sch, Gil Heart Ctr, Vasc Med & Atherosclerosis Unit, Inchon 405760, South Korea
[2] Gachon Med Sch, Lab Med, Inchon, South Korea
关键词
HMG-CoA reductase inhibitor; angiotensin converting enzyme inhibitor; endothelial function; hypercholesterolemia; coronary artery disease;
D O I
10.1016/j.atherosclerosis.2004.06.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because the mechanisms of the biological effects of statin and angiotensin converting enzyme inhibitor therapies differ, we studied the vascular responses to these therapies in hypercholesterolemic patients with coronary artery disease. We administered simvastatin 20 mg and placebo or ramipril 10 mg daily during 2 months with washout 2 months to 32 hypercholesterolemic patients with coronary artery disease. This study was randomized, double-blind, placebo-controlled, crossover in design. Simvastatin alone or combined with ramipril significantly changed lipoproteins, and improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements by 33 +/- 6% and by 50 +/- 14%, respectively (both P < 0.001) and reduced plasma levels of nitrate relative to baseline measurements (P = 0.413 and 0.037, respectively), the plasma NIDA levels relative to baseline measurements by 8 +/- 8% and by 18 +/- 9% (P = 0.039 and P < 0.001, respectively) and MCP-1 relative to baseline measurements by 7 +/- 4% and by 13 +/- 3%, respectively (P = 0.019 and P < 0.001, respectively), and CRP from 0.22 to 0.14 mg/dl and from 0.22 to 0.15 mg/dl, respectively (P = 0.124 and 0.002, respectively), and PAI-1 antigen relative to baseline measurements (P = 0.690 and 0.018, respectively). However, simvastatin combined with ramipril changed to greater but statistically insignificant extent the percent flow-mediated dilator response to hyperemia and plasma levels of nitrate, NIDA, MCP-1, and PAI-1 antigen than simvastatin alone. Simvastatin alone or combined with ramipril showed significant beneficial effects on endothelial function in hypercholesterolemic patients with coronary artery disease. However, simvastatin combined with ramipril did not significantly change, compared with simvastatin alone. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:147 / 153
页数:7
相关论文
共 56 条
[1]   THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION [J].
ANDERSON, TJ ;
MEREDITH, IT ;
YEUNG, AC ;
FREI, B ;
SELWYN, AP ;
GANZ, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) :488-493
[2]   Interaction between chemokines and oxidative stress:: Possible pathogenic role in acute coronary syndromes [J].
Aukrust, P ;
Berge, RK ;
Ueland, T ;
Aaser, E ;
Damås, JK ;
Wikeby, L ;
Brunsvig, A ;
Müller, F ;
Forfang, K ;
Froland, SS ;
Gullestad, L .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :485-491
[3]   HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells [J].
Bourcier, T ;
Libby, P .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :556-562
[4]   NEGATIVE FEEDBACK-REGULATION OF ENDOTHELIAL-CELL FUNCTION BY NITRIC-OXIDE [J].
BUGA, GM ;
GRISCAVAGE, JM ;
ROGERS, NE ;
IGNARRO, LJ .
CIRCULATION RESEARCH, 1993, 73 (05) :808-812
[5]  
Buttery LDK, 1996, LAB INVEST, V75, P77
[6]   Increased activity of endogenous endothelin in patients with hypercholesterolemia [J].
Cardillo, C ;
Kilcoyne, CM ;
Cannon, RO ;
Panza, JA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (05) :1483-1488
[7]   Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty [J].
Cipollone, F ;
Marini, M ;
Fazia, M ;
Pini, B ;
Iezzi, A ;
Reale, M ;
Paloscia, L ;
Materazzo, G ;
D'Annunzio, E ;
Conti, P ;
Chiarelli, F ;
Cuccurullo, F ;
Mezzetti, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :327-334
[8]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[9]   Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice [J].
Daugherty, A ;
Manning, MW ;
Cassis, LA .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) :1605-1612
[10]   Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor [J].
Dechend, R ;
Fiebeler, A ;
Park, JK ;
Muller, DN ;
Theuer, J ;
Mervaala, E ;
Bieringer, M ;
Gulba, D ;
Dietz, R ;
Luft, FC ;
Haller, H .
CIRCULATION, 2001, 104 (05) :576-581